The company said its new KHINDIVI formulation showed bioequivalence to ALKINDI SPRINKLE, supporting a label expansion beyond the current approval for pediatric patients age 5 and older, with potential approval in the first half of 2027.
verifying reliability
No specialized terms available for this topic.